echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > ASCO 2020: K-drug-combination lunvanini's "cola combination" re-emerges in renal transparent cell carcinoma

    ASCO 2020: K-drug-combination lunvanini's "cola combination" re-emerges in renal transparent cell carcinoma

    • Last Update: 2020-06-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In Phase II clinical study Keynote-146, 104 patients with metastatic transparent cell renal cell carcinoma were treatedPaboli-Zandi (
    K drug) combined with lendatinib, also known as the cola combinationThese patients have previously received 2 to 3 treatments, such as PD-1/L1 therapy, PD-1/L1 combined with other anti-angivedosis, or O-Y double immunotherapy, which is in the group of PD-1/L1 drug-resistant patientseven in patients with PD-1/L1-resistant kidney cancer, the cola combination still achieved an effective rate of 55%, and the median reaction duration (DOR) reached 12 months, clinical performance is excellent, providing new solutions for PD-1/L1 drug-resistant patientsFDA accelerates approval of PD-1 inhibitor son
    Keytruda (K drug) in conjunction with Lenvima ," a "cola combination"used to treat patients with specific advanced endometrial cancerThese patients are patients whose progressosts of the disease after systemic treatment are not suitable for surgery or radiotherapy and are not associated with microsatellite instability (MSI-H) or mismatchedrepair defects (dMMR)This is the first time that the Cola combination has been approved by the FDA for an indication that not only that, but also that of Oralia and Canada, have also approved the applicationAs early as the 2016 ESMO Conference, the summary of Phase I clinical study of the joint Pablo Zumamono-treated physical tumor of Lonvastini entered the public eye for the first time and attracted the attention of experts and scholarsThe main observation endpoint of this study was the maximum tolerable dose and safety of the drug, including a total of 13 patients, including 8 cases of kidney cancer, 2 cases of endometrial cancer, 2 cases of non-small cell lung cancer, 1 case of melanomaOf the 13 patients, 7 achieved partial remission, the objective remission rate reached 54%, and none of the patients had disease progress, the disease control rate was as high as 100%also reported at the 2017 ASCO conference on a study on the treatment of renal transparent cell carcinoma in the combination of luvalatinib and Paboli zumaThe study enrolled a total of 30 patients with renal transparent cell carcinoma in a similar treatment to the dose reported at the 2015 ESMO conference The objective remission rate of 30 patients at 24 weeks was 63%, while in the first treatment patients, the objective remission rate was 83%, and the disease control rate reached 100% Based on the above findings, the FDA also approved the identification of the breakthrough therapy for the treatment of advanced renal transparent cell carcinoma in combination with the PD1 inhibitor (Pabloli-zumatist) The 2018 ASCO Conference updated the long-term follow-up results of the above-mentioned combination of treatments for patients with renal transparent cell carcinoma, with a median PFS of 18 months, significant efficacy, and an objective remission rate of 63.3% for 24 weeks, which is also a very good result However, in this study, the incidence of adverse events is also high, 30 patients have 22 adverse events, the occurrence rate of 73%, the main adverse events are mostly related to lunvastini, mainly in hypertension, proteinuria and so on Although the incidence of adverse reactions is high, relatively speaking, adverse reactions are controllable The approval is based on the results of a clinical trial of the single-arm II KEYNOTE-146/Study 111 , which included 94 patients with non-MSI-H or dMMR endometrial cancer tumors who took 20mg of renvadini daily , intravenously 200mg Keytruda every 3 weeks until the condition worsened or an unacceptable toxicity response occurred found that the total response rate (ORR) of was 38.3% , of which 10 (10.6%) patients were fully remission CR and 26 (27.7%) patients were partially resoactive PR 69% (n - 25) patients had a response duration (DOR) of 6 months Common adverse events (AEs) are fatigue, high blood pressure, musculoskeletal pain, diarrhea, loss of appetite, hypothyroidism, nausea and stomatitis in the study of liver cancer, but showed another result It is worth noting that the dose applied in the study of hepatocellular carcinoma is relatively small, using doses of 12 mg and 8 mg, while the Paboli bead mono-anti-dose is the same The results showed that for non-restoctable hepatocellular carcinoma, the objective remission rate was as high as 42.3% ,30,Part2203.6,26.9%,PFS9.69,20183,23。 For patients with hepatocellular carcinoma, the efficacy of combination therapy is better than that of the existing treatment However, treatment-related adverse reactions were also observed in all three studies, particularly with a incidence of 60 to 70 per cent of stage3 to 4 adverse reactions, similar to the first previously reported study at the 2019 AACR Conference, a study on the safety and efficacy of Paboli-Zumas (K-drug) combined with levastinib (Levastinib) to treat non-reprecision hepatocellular carcinoma scored updates that the combination therapy achieved a 50% efficiency and 93.3% control rate, giving new hope to patients with advanced liver cancer The patient took 12 mg (weight s 60kg) or 8mg (weight 60kg) once daily; the FDA has awarded Keytruda and Lenvima combination therapies to advanced, non-reprectoable patients with advanced, non-reprectoable hepatocellular carcinoma (HCC) for first-line treatment that cannot be partially treated since the treatment model of Pablo Zumai single anti-corollum alcanibini has shown excellent efficacy in multiple solid tumors, this immuno-joint treatment model is also very consistent with the future research direction of immunotherapy, its research results in other solid tumors further expansion and promotion is very much to look forward to! author: MedSci Source: MedSci Original
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.